BioLife Solutions pullback creates buying opportunity, says Northland

Northland analyst Carl Byrnes reiterates BioLife Solutions (BLFS) as a “Top Pick 2026” and views the recent pullback as “a compelling buying opportunity” given improving fundamentals and its re-established pure-play status. BioLife’s biopreservation media platform has emerged as the standard in cell and gene therapy, says the analyst, who sees FY26 revenue guidance that equates to a 17%-20% year-over-year increase “reinforcing durable growth.”